GLP1R and type 2 diabetes mellitus: GLP-1 receptor agonists seem to have anti-inflammatory effects in animal models and reduce inflammation and biomarkers in patients with T2D nonetheless, there are insufficient data as to their use in critically ill or COVID-19 [73].